Estimates of comparative persistence with TNF antagonists in RA patients remain controversial and estimates could not be pooled due to differences in measures of persistence (e.g. median, mean, percentage of persistent patients after 1-year) [22], [23]. The gene discussed is TNF; the disease is rheumatoid arthritis.